Sign Up to Receive Your Personalised Learning Resources
Start Learning
Mark Lawler, European Cancer Summit 2022: The ECO-ASCO Special Network
Helena Ullgren: PrEvCan | Focus on alcohol and cancer prevention
Less talking. More doing. The current status of EU cancer policy
Michael Pishvaian, AACR 2023: Challenges in the treatment of locally advanced pancreatic cancer
Ryan Sullivan, AACR 2023: The STARBOARD phase III trial, encorafenib, binimetinib and pembrolizumab as a combination therapy for BRAF V600 mutant melanoma
Saskia Middeldorp, ASH 2022: The efficacy of low-molecular-weight heparin in women with recurrent miscarriage and inherited thrombophilia – the ALIFE 2 trial
Advances in immunotherapies and targeted treatments for patients with bladder cancer: An update from ESMO 2022
Lisa Sarfaty: Help support Rare Disease Day
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
Sign up to view Favourites, Keep Notes and Track CME Credits
Favourites
Durvalumab: A PD-L1 Blocking Antibody for the Treatment of Adult Patients with Locally Advanced or Metastatic Biliary Tract Cancer
View
Carmelo Rizzari: An overview of SIOP Europe
View
Selecting the optimal treatment for patients with chronic myeloid leukaemia after two prior lines of therapy
View
John Mascarenhas, ASH 2022: Pacritinib for the treatment of myelofibrosis and severe thrombocytopenia, the PACIFICA study
View
Sara Tolaney, ASCO 2023: Primary outcome analysis of the phase 3 SONIA trial and the final overall survival results from the phase 3 TROPiCS-02 study
View
Kim Benstead, European Cancer Summit, 2022: Technical advances in cancer training in Europe
View
Mark Litzow, ASH 2022: Blinatumomab for BCR::ABL1 negative B-lineage acute lymphoblastic leukaemia, ECOG-ACRIN E1910 (a phase III study)
View
Ajay Aggarwal, European Cancer Summit 2022: Perspectives of young cancer professionals
View
Lisa Sarfaty: Exploring and addressing inequities in rare diseases
View
Optimizing androgen deprivation therapy (ADT) in advanced prostate cancer
View